1. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice
- Author
-
Barzel, A., Paulk, N. K., Shi, Y., Huang, Y., Chu, K., Zhang, F., Valdmanis, P. N., Spector, L.P., Porteus, M.H., Gaensler, K.M., and Kay, M.A.
- Subjects
Gene therapy -- Methods ,Hemophilus infections -- Care and treatment ,Hemophilus influenzae -- Health aspects ,Environmental issues ,Science and technology ,Zoology and wildlife conservation - Abstract
Promoterless recombinant adeno-associated virus is used without nucleases to target the human coagulation factor IX gene to the liver-expressed albumin locus in haemophilia B mice, with an on-target integration into ~0.5% of the albumin alleles in hepatocytes; stable F9 plasma levels at 7-20% of normal were obtained, leading to normal coagulation times in treated factor-IX-deficient mice. Nuclease-free genome targeting less risky Most genome editing applications under consideration for therapeutic use require the presence of a site-specific endonuclease, but the uncontrolled presence of endonucleases in tissues can potentially cause significant adverse effects. Here, Mark Kay and colleagues describe the use of promoterless recombinant adeno-associated virus to target -- without the need for nucleases -- the human coagulation factor IX gene to the liver-expressed albumin locus in haemophilia B mice. The approach achieves on-target integration into about 0.5% of the albumin alleles in hepatocytes. Stable F9 plasma levels in treated factor IX deficient mice were 7-20% of normal, leading to coagulation times within the normal range. Site-specific gene addition can allow stable transgene expression for gene therapy. When possible, this is preferred over the use of promiscuously integrating vectors, which are sometimes associated with clonal expansion.sup.1 and oncogenesis.sup.2. Site-specific endonucleases that can induce high rates of targeted genome editing are finding increasing applications in biological discovery and gene therapy.sup.3. However, two safety concerns persist: endonuclease-associated adverse effects, both on-target.sup.4 and off-target.sup.5,6; and oncogene activation caused by promoter integration, even without nucleases.sup.7. Here we perform recombinant adeno-associated virus (rAAV)-mediated promoterless gene targeting without nucleases and demonstrate amelioration of the bleeding diathesis in haemophilia B mice. In particular, we target a promoterless human coagulation factor IX (F9) gene to the liver-expressed mouse albumin (Alb) locus. F9 is targeted, along with a preceding 2A-peptide coding sequence, to be integrated just upstream to the Alb stop codon. While F9 is fused to Alb at the DNA and RNA levels, two separate proteins are synthesized by way of ribosomal skipping. Thus, F9 expression is linked to robust hepatic albumin expression without disrupting it. We injected an AAV8-F9 vector into neonatal and adult mice and achieved on-target integration into ~0.5% of the albumin alleles in hepatocytes. We established that F9 was produced only from on-target integration, and ribosomal skipping was highly efficient. Stable F9 plasma levels at 7-20% of normal were obtained, and treated F9-deficient mice had normal coagulation times. In conclusion, transgene integration as a 2A-fusion to a highly expressed endogenous gene may obviate the requirement for nucleases and/or vector-borne promoters. This method may allow for safe and efficacious gene targeting in both infants and adults by greatly diminishing off-target effects while still providing therapeutic levels of expression from integration., Author(s): A. Barzel [sup.1] , N. K. Paulk [sup.1] , Y. Shi [sup.2] , Y. Huang [sup.1] , K. Chu [sup.1] , F. Zhang [sup.1] , P. N. Valdmanis [sup.1] [...]
- Published
- 2015
- Full Text
- View/download PDF